Oncopeptides to present at the Jefferies Healthcare Conference in New York on June 7th

Stockholm – May 29, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies annual Healthcare Conference in New York on June 7th at 1.30PM EST, the presentation will be webcasted.

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate Ygalo®, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma.

Ygalo® has been used to treat late-stage RRMM patients in both phase I and phase II clinical studies (O-12-M1) with favorable results. Currently, Ygalo® is being studied in three clinical trials for the treatment of multiple myeloma. The current studies are HORIZON, OCEAN and ANCHOR. A fourth study, BRIDGE in RRMM patients with impaired renal function will be initiated during Q3 this year to further investigate Ygalo® in multiple myeloma.

The current clinical study program is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

About Oncopeptides

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate Ygalo®, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program of Ygalo® is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Visit www.oncopeptides.se for more information.

For further information, please contact:  

Rein Piir, Head of Investor Relations, Oncopeptides
E-mail: rein.piir@oncopeptides.se

This information was submitted for publication at 09.00 CET, May 29, 2018

Tags: